Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Advertisement

Advertisement




Aug
04
Today In Oncology
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
AI-Based cfDNA Fragmentome Classifier May Improve Detection of HCC
Next-Generation Sequencing Uptake Remains Low Among Medicare Beneficiaries, Study Finds
U.S. News & World Report Announces 2026–2027 Best Cancer Hospitals
TOPAZ-1 Post Hoc Analysis Supports Durvalumab Plus Chemotherapy in Advanced Biliary Tract Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo